Ionis Pharmaceuticals, Inc.
IONS
$37.31
-$0.31-0.82%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 119.50M | 324.51M | 144.21M | 188.41M | 130.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 119.50M | 324.51M | 144.21M | 188.41M | 130.52M |
| Cost of Revenue | 216.37M | 257.96M | 217.52M | 232.46M | 199.16M |
| Gross Profit | -96.87M | 66.55M | -73.31M | -44.05M | -68.63M |
| SG&A Expenses | 52.64M | 51.01M | 69.95M | 46.14M | 45.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 269.01M | 308.97M | 287.47M | 278.61M | 244.67M |
| Operating Income | -149.51M | 15.54M | -143.27M | -90.20M | -114.15M |
| Income Before Tax | -142.73M | -2.77M | -140.81M | -77.45M | -112.94M |
| Income Tax Expenses | 75.00K | 6.50M | 6.60M | 7.84M | 11.38M |
| Earnings from Continuing Operations | -142.80M | -9.26M | -147.41M | -85.29M | -124.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -142.80M | -9.26M | -147.41M | -85.29M | -124.32M |
| EBIT | -149.51M | 15.54M | -143.27M | -90.20M | -114.15M |
| EBITDA | -146.33M | 18.74M | -140.08M | -86.94M | -110.94M |
| EPS Basic | -0.98 | -0.06 | -1.03 | -0.60 | -0.87 |
| Normalized Basic EPS | -0.62 | 0.08 | -0.61 | -0.34 | -0.49 |
| EPS Diluted | -0.98 | -0.06 | -1.03 | -0.60 | -0.87 |
| Normalized Diluted EPS | -0.62 | 0.08 | -0.61 | -0.34 | -0.49 |
| Average Basic Shares Outstanding | 145.54M | 144.00M | 143.32M | 143.10M | 142.74M |
| Average Diluted Shares Outstanding | 145.54M | 144.00M | 143.32M | 143.10M | 142.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
